Log in to search using one of your social media accounts:

 

Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 28, 2016 Category: American Health Source Type: news

CDC Offers Recommendations for Expanded Indication of Hib Vaccine (FREE)
By the Editors The CDC has published updated guidance on the use of the Haemophilus influenza type B vaccine Hiberix … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 28, 2016 Category: Primary Care Source Type: news

FDA Approves Expanded Use of GSK Hib Vaccine From Booster Dose To Full Series
Philadelphia, 15 January 2016 -- GSK [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration approved an expanded age indication for Hiberix [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]. Hiberix is now indicated... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 14, 2016 Category: Drugs & Pharmacology Source Type: news

How A Claim That A Childhood Vaccine Prevents Leukemia Went Too Far
It seemed to make sense that the childhood Hib vaccine could cut leukemia risk by keeping the immune system in check. But proving there's cause and effect at work turns out to be a challenge.» E-Mail This (Source: NPR Health and Science)
Source: NPR Health and Science - May 27, 2015 Category: Consumer Health News Authors: Tara Haelle Source Type: news

How early childhood vaccination reduces leukemia risk
A team of researchers has discovered how a commonly administered vaccine protects against acute lymphoblastic leukemia, the most common type of childhood cancer. The Haemophilus influenzae Type b (Hib) vaccine not only prevents ear infections and meningitis caused by the Hib bacterium, but also protects against ALL, which accounts for approximately 25 percent of cancer diagnoses among children younger than 15 years. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 18, 2015 Category: Science Source Type: news

Richard A. Insel, M.D.
Chief Scientific OfficerRichard A. Insel, M.D., oversees the research strategy of JDRF, the world’s largest funder of type 1 diabetes (T1D) research. Prior to joining JDRF in 2003, Dr. Insel was the founding director of the Center for Human Genetics and Molecular Pediatric Disease and professor of pediatrics and microbiology and immunology at the University of Rochester Medical Center. During his 26-year affiliation with the university’s medical center, he served as the acting chair of pediatrics, director of the Strong Children’s Research Center, and chief of the division of pediatric immunology, allergy...
Source: PHRMA - March 12, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Richard A. Insel, M.D.
JDRF Chief Scientific OfficerRichard A. Insel, M.D., oversees the research strategy of JDRF, the world’s largest funder of type 1 diabetes (T1D) research. Prior to joining JDRF in 2003, Dr. Insel was the founding director of the Center for Human Genetics and Molecular Pediatric Disease and professor of pediatrics and microbiology and immunology at the University of Rochester Medical Center. During his 26-year affiliation with the university’s medical center, he served as the acting chair of pediatrics, director of the Strong Children’s Research Center, and chief of the division of pediatric immunology, al...
Source: PHRMA - February 14, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

ACIP Issues New Hib Statement
(MedPage Today) -- The Advisory Committee on Immunization Practices has approved the first statement on routine Haemophilus influenzae type b (Hib) vaccination since 1993. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 21, 2013 Category: American Health Source Type: news